Wheeler, David C.

Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program

Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Blais, J., Li, Q., Jardine, M. J., et al. (2021) · American Journal of Kidney Diseases

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 70

Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial

Heerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 56

Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials

Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 40

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L. (2018) · Nephrology Dialysis Transplantation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 22

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 18

Does lipid-lowering therapy slow progression of chronic kidney disease?

Wheeler, D. C. (2004) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 11

Individualised treatment effects of corticosteroids in IgA nephropathy

Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 2